Vipera latastei venom protein toxins

Vipera latastei venom protein toxins represent a complex mixture of bioactive proteins and peptides secreted by the venom glands of the Lataste's viper (Vipera latastei), a species endemic to the Iberian Peninsula and North Africa [1.3.1]. The venom is primarily composed of four major protein families: snake venom metalloproteinases (SVMPs), phospholipases A2 (PLA2s), snake venom serine proteases (SVSPs), and C-type lectin-like proteins (CTLPs) [1.3.1, 1.4.2]. These toxins act synergistically to disrupt the prey's physiological systems, primarily targeting the hemostatic system and causing local tissue damage [1.2.3, 1.3.3]. SVMPs and SVSPs are largely responsible for hemorrhage and coagulopathy, while PLA2s contribute to myotoxicity and inflammation [1.2.4, 1.4.2]. In clinical settings, these toxins are the primary targets for antivenom therapy, such as Inoserp Europe, which contains antibodies raised against V. latastei venom [1.4.1]. Additionally, specific toxins within this mixture, such as disintegrins, are of interest in drug discovery for their ability to inhibit platelet aggregation and cell adhesion [1.1.1, 1.3.3]. Small molecule inhibitors like varespladib and marimastat are also being investigated as potential adjuncts or alternatives to traditional antivenoms to neutralize specific enzymatic components of the venom [1.2.1].

Other names

Lataste's viper venomSnub-nosed viper venomVipera latastei toxinsVipera latastei gaditana venom

The primary mechanism of action for drugs targeting Vipera latastei venom protein toxins involves the neutralization of toxic components by specific antibodies (antivenom) or the inhibition of enzymatic activities by small molecule inhibitors [1.2.1, 1.4.1]. Antivenoms like Inoserp Europe contain polyvalent F(ab')2 fragments that bind to and sequester venom proteins, preventing their interaction with physiological targets [1.4.4]. Small molecule inhibitors such as varespladib target the active site of phospholipase A2 (PLA2) enzymes, while metalloproteinase inhibitors like marimastat and prinomastat chelate the zinc ion required for the catalytic activity of snake venom metalloproteinases (SVMPs) [1.2.1].